These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

49 related articles for article (PubMed ID: 1664616)

  • 1. [Effectiveness of amiridin in senile dementia of the Alzheimer type].
    Bukatina EE; Grigor'eva IV; Sokol'nik EI
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1991; 91(9):53-8. PubMed ID: 1664616
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Double-blind placebo-controlled study with citicoline in APOE genotyped Alzheimer's disease patients. Effects on cognitive performance, brain bioelectrical activity and cerebral perfusion.
    Alvarez XA; Mouzo R; Pichel V; Pérez P; Laredo M; Fernández-Novoa L; Corzo L; Zas R; Alcaraz M; Secades JJ; Lozano R; Cacabelos R
    Methods Find Exp Clin Pharmacol; 1999 Nov; 21(9):633-44. PubMed ID: 10669911
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atomoxetine augmentation of cholinesterase inhibitor therapy in patients with Alzheimer disease: 6-month, randomized, double-blind, placebo-controlled, parallel-trial study.
    Mohs RC; Shiovitz TM; Tariot PN; Porsteinsson AP; Baker KD; Feldman PD
    Am J Geriatr Psychiatry; 2009 Sep; 17(9):752-9. PubMed ID: 19700948
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effectiveness of amiridin in senile dementia of the Alzheimer's type.
    Bukatina EE; Grigor'eva IV; Sokol'chik EI
    Neurosci Behav Physiol; 1993; 23(1):83-9. PubMed ID: 8464548
    [No Abstract]   [Full Text] [Related]  

  • 5. Relationship between pharmacodynamic activity and cognitive effects of eptastigmine in patients with Alzheimer's disease. Eptastigmine Study Group.
    Canal N; Imbimbo BP
    Clin Pharmacol Ther; 1996 Aug; 60(2):218-28. PubMed ID: 8823240
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting.
    Tariot PN; Cummings JL; Katz IR; Mintzer J; Perdomo CA; Schwam EM; Whalen E
    J Am Geriatr Soc; 2001 Dec; 49(12):1590-9. PubMed ID: 11843990
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Double-blind, randomized, placebo-controlled pilot study with anapsos in senile dementia: effects on cognition, brain bioelectrical activity and cerebral hemodynamics.
    Alvarez XA; Pichel V; Pérez P; Laredo M; Corzo D; Zas R; Fernández-Novoa L; Sempere JM; Díaz J; Cacabelos R
    Methods Find Exp Clin Pharmacol; 2000 Sep; 22(7):585-94. PubMed ID: 11196347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness and safety of velnacrine for the treatment of Alzheimer's disease. A double-blind, placebo-controlled study. Mentane Study Group.
    Antuono PG
    Arch Intern Med; 1995 Sep; 155(16):1766-72. PubMed ID: 7654110
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral physostigmine treatment for patients with presenile and senile dementia of the Alzheimer's type: a double-blind placebo-controlled trial.
    Jenike MA; Albert MS; Heller H; Gunther J; Goff D
    J Clin Psychiatry; 1990 Jan; 51(1):3-7. PubMed ID: 2403997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IDEAL: a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease.
    Winblad B; Grossberg G; Frölich L; Farlow M; Zechner S; Nagel J; Lane R
    Neurology; 2007 Jul; 69(4 Suppl 1):S14-22. PubMed ID: 17646619
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of tablet huperzine-A on memory, cognition, and behavior in Alzheimer's disease.
    Xu SS; Gao ZX; Weng Z; Du ZM; Xu WA; Yang JS; Zhang ML; Tong ZH; Fang YS; Chai XS
    Zhongguo Yao Li Xue Bao; 1995 Sep; 16(5):391-5. PubMed ID: 8701750
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of acetaminophen on behavior, well-being, and psychotropic medication use in nursing home residents with moderate-to-severe dementia.
    Chibnall JT; Tait RC; Harman B; Luebbert RA
    J Am Geriatr Soc; 2005 Nov; 53(11):1921-9. PubMed ID: 16274373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selegiline in the treatment of Alzheimer's disease: a long-term randomized placebo-controlled trial. Czech and Slovak Senile Dementia of Alzheimer Type Study Group.
    Filip V; Kolibás E
    J Psychiatry Neurosci; 1999 May; 24(3):234-43. PubMed ID: 10354658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Cognitive enhancement effect of piracetam in patients with mild cognitive impairment and dementia].
    Tariska P; Paksy A
    Orv Hetil; 2000 May; 141(22):1189-93. PubMed ID: 10853348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The selective muscarinic agonist xanomeline improves both the cognitive deficits and behavioral symptoms of Alzheimer disease.
    Bodick NC; Offen WW; Shannon HE; Satterwhite J; Lucas R; van Lier R; Paul SM
    Alzheimer Dis Assoc Disord; 1997; 11 Suppl 4():S16-22. PubMed ID: 9339268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The influence of cerebrolysin on the efficiency of subsequent therapy with amiridine++ in Alzheimer's disease patients (neuropsychological investigation)].
    Roshchina IF; Kolykhalov IV; Selezneva ND; Zharikov GA; Gerasimov NP; Gavrilova SI
    Zh Nevrol Psikhiatr Im S S Korsakova; 1999; 99(12):43-6. PubMed ID: 10629930
    [TBL] [Abstract][Full Text] [Related]  

  • 17. No evidence for cognitive improvement from oral nicotinamide adenine dinucleotide (NADH) in dementia.
    Rainer M; Kraxberger E; Haushofer M; Mucke HA; Jellinger KA
    J Neural Transm (Vienna); 2000; 107(12):1475-81. PubMed ID: 11459000
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Problems in the search for cognition enhancers.
    Hollister LE
    Pharmacopsychiatry; 1990 Feb; 23 Suppl 2():33-6. PubMed ID: 2186410
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Choline chloride fails to improve cognition of Alzheimer's disease.
    Thal LJ; Rosen W; Sharpless NS; Crystal H
    Neurobiol Aging; 1981; 2(3):205-8. PubMed ID: 7312098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral physostigmine as treatment for dementia of the Alzheimer type: a long-term outpatient trial.
    Jenike MA; Albert MS; Baer L
    Alzheimer Dis Assoc Disord; 1990; 4(4):226-31. PubMed ID: 2264980
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.